What do the PORTEC (Post‑Operative Radiation Therapy in Endometrial Carcinoma) trials recommend for adjuvant treatment of endometrial cancer based on risk categories?

PORTEC Trials for Endometrial Cancer: Risk-Based Adjuvant Treatment Recommendations

The PORTEC trials established that adjuvant treatment for endometrial cancer should be stratified by risk category, with vaginal brachytherapy for intermediate-risk disease, external beam radiotherapy for high-intermediate risk, and combined chemoradiotherapy for high-risk disease—particularly those with p53-abnormal molecular profiles who derive the greatest survival benefit from systemic therapy. 1

Risk Stratification Framework

The PORTEC trials fundamentally changed how we approach adjuvant therapy by defining specific risk categories based on age, grade, depth of myometrial invasion, and lymphovascular space invasion (LVSI). The most recent 2025 ESGO-ESTRO-ESP guidelines now integrate molecular classification, which provides superior prognostic discrimination 1.

Low-Risk Disease

• No adjuvant therapy recommended (Level I, Grade A evidence) 1
• Includes: Stage IA POLEmut, MMRd, or NSMP low-grade with positive estrogen receptor
• PORTEC-1 demonstrated that external beam radiotherapy (EBRT) reduced locoregional recurrence from 15.5% to 6% at 15 years, but provided no overall survival benefit 2
• Key pitfall: Avoid overtreatment in this group—EBRT should be avoided as it increases long-term risk of second cancers without survival benefit 2

Intermediate-Risk Disease

• Vaginal brachytherapy is the standard of care (Level I, Grade A evidence) 1, 3
• Includes: Stage IB MMRd or NSMP low-grade with positive estrogen receptor
• PORTEC-2 definitively showed vaginal brachytherapy provides equivalent vaginal and pelvic control to EBRT with significantly less toxicity 3, 4
• 10-year vaginal recurrence: 3.4% with brachytherapy vs 2.4% with EBRT (not significant) 4
• Observation alone is acceptable for patients <60 years or with low-grade disease 1

High-Intermediate Risk Disease

• External beam radiotherapy is recommended for optimal pelvic control (Level II, Grade A evidence) 1
• Includes: Stage IIA MMRd, Stage IIB MMRd or NSMP low-grade, Stage IIC MMRd with cervical invasion or substantial LVSI
• Vaginal brachytherapy is an alternative if lymph node staging performed and pN0 1
• PORTEC-1 and PORTEC-2 pooled analysis identified age, tumor grade, and LVSI as highly predictive for recurrence 3
• Critical caveat: PORTEC-1 and PORTEC-2 excluded stage IB grade 3 disease, making brachytherapy alone controversial in this subset 3

High-Risk Disease

For high-risk endometrial cancer, combined chemoradiotherapy significantly improves failure-free survival compared to radiotherapy alone, with the greatest benefit in p53-abnormal tumors. 3, 5

PORTEC-3 Trial Results:

• 5-year overall survival: 81.8% with chemoradiotherapy vs 76.7% with radiotherapy alone (HR 0.76, p=0.11) 5
• 5-year failure-free survival: 75.5% vs 68.6% (HR 0.71, p=0.022) 5
• Molecular subgroup analysis revealed critical differences 6:
  • p53-abnormal: 59% vs 36% 5-year RFS (p=0.019)—clear benefit from chemotherapy
  • POLEmut: 100% vs 97% (excellent prognosis regardless)
  • MMRd: 68% vs 76% (no benefit from chemotherapy)
  • NSMP: 80% vs 68% (trend toward benefit)

Treatment Algorithm for High-Risk Disease:

1. Obtain molecular classification (p53, MMR, POLE status) 1, 6
2. p53-abnormal tumors: Combined chemoradiotherapy (cisplatin during RT, followed by carboplatin/paclitaxel) 3, 6
3. POLEmut tumors: Consider observation or reduced treatment given excellent prognosis 6
4. MMRd and NSMP: Individualize based on stage and other risk factors 6

Toxicity Considerations:

• Grade 3+ adverse events: 60% with chemoradiotherapy vs 12% with radiotherapy alone 5, 7
• Persistent sensory neuropathy (grade 2+): 25% at 24 months with chemoradiotherapy vs <1% with radiotherapy alone 7
• Most toxicity resolves by 12 months except neuropathy 7

Stage III Disease

For stage III disease, combined chemoradiotherapy is strongly recommended based on PORTEC-3 showing greatest benefit in this subgroup 3. The GOG-258 trial showed chemotherapy alone had equivalent recurrence-free survival to chemoradiotherapy, but increased pelvic failures 3.

Critical Clinical Pearls

• L1CAM expression, p53-mutant status, and substantial LVSI are risk factors requiring more aggressive treatment 4
• Subclonal p53 staining strongly indicates POLEmut or MMRd tumors—do not classify as p53-abnormal 8
• Lymph node staging status matters: If comprehensive staging performed and pN0, can de-escalate from EBRT to brachytherapy in high-intermediate risk 1
• Age >60 years is a consistent adverse prognostic factor across all PORTEC trials 3, 2

Ongoing Evolution

The PORTEC-4a trial is investigating molecular profile-based treatment tailoring in high-intermediate risk disease, comparing observation, brachytherapy, or EBRT based on molecular classification versus standard brachytherapy for all 9. Results expected in 2023-2024 will further refine these recommendations.

The integration of molecular classification represents the most significant advance in endometrial cancer risk stratification, allowing identification of patients who truly benefit from intensive treatment (p53-abnormal) versus those with excellent prognosis who can avoid treatment toxicity (POLEmut). 1, 6